SCHEMBL13696544

SCHEMBL13696544

NCCCCNC(=O)C[C@@H]1[C@@H](Nc2nccc(N3CCCCCCC3)n2)CCCN1C1CCCCC1

nearest known ligand 0.45

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ CXCR4 P61073 2/20 0.45
▸ HRH4 Q9H3N8 7/20 0.37
▸ HDAC3 O15379 2/20 0.35
▸ HDAC1 Q13547 2/20 0.35
▸ TPSAB1 Q15661 1/20 0.35
▸ TPSD1 Q9BZJ3 1/20 0.35
▸ TPSG1 Q9NRR2 1/20 0.35
▸ CCNK O75909 1/20 0.34
▸ CDK12 Q9NYV4 1/20 0.34
▸ ALK Q9UM73 2/20 0.33
▸ IGF1R P08069 1/20 0.33
▸ ROCK2 O75116 1/20 0.33
▸ MRGPRX1 Q96LB2 1/20 0.33
▸ PDGFRA P16234 1/20 0.33
▸ CDK2 P24941 1/20 0.33
▸ FLT3 P36888 1/20 0.33
▸ SYK P43405 1/20 0.33
▸ HSD11B1 P28845 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2011381 1.00 CXCR4 (0.45) CXCR4HRH4HDAC3HDAC1TPSAB1
SCHEMBL14391832 0.97 CXCR4 (0.45) CXCR4HRH4HDAC3HDAC1CCNK
SCHEMBL13696542 0.97 CXCR4 (0.45) CXCR4HRH4HDAC3HDAC1CCNK
SCHEMBL2012554 0.97 CXCR4 (0.45) CXCR4HRH4HDAC3HDAC1CCNK
SCHEMBL2014223 0.94 CXCR4 (0.49) CXCR4HRH4CCNKCDK12ALK
SCHEMBL13696545 0.94 CXCR4 (0.49) CXCR4HRH4CCNKCDK12ALK
SCHEMBL4115339 0.90 CXCR4 (0.45) CXCR4HRH4HDAC3HDAC1CCNK
SCHEMBL13696558 0.89 HRH4 (0.38) CXCR4HRH4CCNKCDK12ALK
SCHEMBL2010696 0.89 HRH4 (0.38) CXCR4HRH4CCNKCDK12ALK
SCHEMBL4122185 0.82 CXCR4 (0.47) CXCR4HRH4HDAC3HDAC1ALK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8680092-B2 Nitrogenous heterocyclic compound and medicinal use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2014-03-25 — — US disclosed
US-8680092-B2 Nitrogenous heterocyclic compound and medicinal use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2014-03-25 — — US disclosed
US-20090233908-A1 NITROGENOUS HETEROCYCLIC COMPOUND AND MEDICINAL USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2009-09-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233908-A1 NITROGENOUS HETEROCYCLIC COMPOUND AND MEDICINAL USE THEREOF CXCR4, CXCR1, CXCL12 CXCR4 1/4885HRH4 152/4885HDAC3 1338/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback